Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease
- aDepartment of Neurology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095;
- Departments of bCellular and Molecular Neurobiology and
- cEnvironmental Science and Engineering, California Institute of Technology, Pasadena, CA 91125;
- Departments of dMolecular Toxicology and
- gMolecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095;
- Departments of eEpidemiology and
- jEnvironmental Health Sciences, UCLA Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA 90095;
- fDepartment of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095;
- hDepartment of Environmental Science, Policy, and Management, University of California, Berkeley, CA 94720;
- iDepartment of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA 90089; and
- kParkinson's Disease Research, Education, and Clinical Center, Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, CA 90073
See allHide authors and affiliations
Contributed by John E. Casida, November 27, 2012 (sent for review October 19, 2012)

Abstract
Parkinson disease (PD) is a neurodegenerative disorder particularly characterized by the loss of dopaminergic neurons in the substantia nigra. Pesticide exposure has been associated with PD occurrence, and we previously reported that the fungicide benomyl interferes with several cellular processes potentially relevant to PD pathogenesis. Here we propose that benomyl, via its bioactivated thiocarbamate sulfoxide metabolite, inhibits aldehyde dehydrogenase (ALDH), leading to accumulation of the reactive dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), preferential degeneration of dopaminergic neurons, and development of PD. This hypothesis is supported by multiple lines of evidence. (i) We previously showed in mice the metabolism of benomyl to S-methyl N-butylthiocarbamate sulfoxide, which inhibits ALDH at nanomolar levels. We report here that benomyl exposure in primary mesencephalic neurons (ii) inhibits ALDH and (iii) alters dopamine homeostasis. It induces selective dopaminergic neuronal damage (iv) in vitro in primary mesencephalic cultures and (v) in vivo in a zebrafish system. (vi) In vitro cell loss was attenuated by reducing DOPAL formation. (vii) In our epidemiology study, higher exposure to benomyl was associated with increased PD risk. This ALDH model for PD etiology may help explain the selective vulnerability of dopaminergic neurons in PD and provide a potential mechanism through which environmental toxicants contribute to PD pathogenesis.
Footnotes
- ↵1To whom correspondence should be addressed. E-mail: ectl{at}berkeley.edu.
Author contributions: A.G.F., S.L.R., J.E.C., B.R., and J.M.B. designed research; A.G.F., S.L.R., A.L., N.P.M., H.A.L., K.C.O., and M.C.S. performed research; J.E.C., M.C., and A.S. contributed new reagents/analytic tools; A.G.F., S.L.R., N.P.M., L.B., and N.T.M. analyzed data; and A.G.F., S.L.R., J.E.C., and J.M.B. wrote the paper.
The authors declare no conflict of interest.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1220399110/-/DCSupplemental.
Citation Manager Formats
Article Classifications
- Biological Sciences
- Medical Sciences